Literature DB >> 27031732

Partial Amelioration of Peripheral and Central Symptoms of Huntington's Disease via Modulation of Lipid Metabolism.

Jane Y Chen1, Conny Tran1, Lin Hwang2, Gang Deng3, Michael E Jung3, Kym F Faull2,4, Michael S Levine1,4, Carlos Cepeda1.   

Abstract

BACKGROUND: Huntington's disease (HD) is a fatal, inherited neurodegenerative disorder characterized by uncontrollable dance-like movements, as well as cognitive deficits and mood changes. A feature of HD is a metabolic disturbance that precedes neurological symptoms. In addition, brain cholesterol synthesis is significantly reduced, which could hamper synaptic transmission.
OBJECTIVE: Alterations in lipid metabolism as a potential target for therapeutic intervention in the R6/2 mouse model of HD were examined.
METHODS: Electrophysiological recordings in vitro examined the acute effects of cholesterol-modifying drugs. In addition, behavioral testing, effects on synaptic activity, and measurements of circulating and brain tissue concentrations of cholesterol and the ketone β-hydroxybutyrate (BHB), were examined in symptomatic R6/2 mice and littermate controls raised on normal chow or a ketogenic diet (KD).
RESULTS: Whole-cell voltage clamp recordings of striatal medium-sized spiny neurons (MSNs) from symptomatic R6/2 mice showed increased frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) compared with littermate controls. Incubation of slices in cholesterol reduced the frequency of large-amplitude sIPSCs. Addition of BHB or the Liver X Receptor (LXR) agonist T0901317 reduced the frequency and amplitude of sIPSCs. Surprisingly, incubation in simvastatin to reduce cholesterol levels also decreased the frequency of sIPSCs. HD mice fed the KD lost weight more gradually, performed better in an open field, had fewer stereotypies and lower brain levels of cholesterol than mice fed a regular diet.
CONCLUSIONS: Lipid metabolism represents a potential target for therapeutic intervention in HD. Modifying cholesterol or ketone levels acutely in the brain can partially rescue synaptic alterations, and the KD can prevent weight loss and improve some behavioral abnormalities.

Entities:  

Keywords:  R6/2 model; cholesterol; electrophysiology; ketogenic diet; synaptic activity

Mesh:

Substances:

Year:  2016        PMID: 27031732      PMCID: PMC5002395          DOI: 10.3233/JHD-150181

Source DB:  PubMed          Journal:  J Huntingtons Dis        ISSN: 1879-6397


  75 in total

1.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.

Authors:  G J Klapstein; R S Fisher; H Zanjani; C Cepeda; E S Jokel; M F Chesselet; M S Levine
Journal:  J Neurophysiol       Date:  2001-12       Impact factor: 2.714

Review 2.  The ketogenic diet: what has science taught us?

Authors:  Jong M Rho; Carl E Stafstrom
Journal:  Epilepsy Res       Date:  2011-08-30       Impact factor: 3.045

3.  Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling.

Authors:  Catherine R Wasser; Mert Ertunc; Xinran Liu; Ege T Kavalali
Journal:  J Physiol       Date:  2006-12-14       Impact factor: 5.182

4.  A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease.

Authors:  David N Ruskin; Jessica L Ross; Masahito Kawamura; Tiffany L Ruiz; Jonathan D Geiger; Susan A Masino
Journal:  Physiol Behav       Date:  2011-04-09

5.  Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease.

Authors:  Daniel del Toro; Xavier Xifró; Albert Pol; Sandrine Humbert; Frédéric Saudou; Josep M Canals; Jordi Alberch
Journal:  J Neurochem       Date:  2010-08-12       Impact factor: 5.372

6.  Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus.

Authors:  A H Ganong; C W Cotman
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

7.  Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Authors:  Carlos Cepeda; Laurie Galvan; Sandra M Holley; Shilpa P Rao; Véronique M André; Elian P Botelho; Jane Y Chen; Joseph B Watson; Karl Deisseroth; Michael S Levine
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

8.  Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro.

Authors:  Carl D Holmgren; Marat Mukhtarov; Anton E Malkov; Irina Y Popova; Piotr Bregestovski; Yuri Zilberter
Journal:  J Neurochem       Date:  2009-11-24       Impact factor: 5.372

9.  Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.

Authors:  Fabian Kreilaus; Adena S Spiro; Anthony J Hannan; Brett Garner; Andrew M Jenner
Journal:  J Huntingtons Dis       Date:  2015

10.  Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease.

Authors:  M Valenza; M Marullo; E Di Paolo; E Cesana; C Zuccato; G Biella; E Cattaneo
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

View more
  10 in total

Review 1.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 2.  Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders.

Authors:  Swarup Mitra; Avijit Banik; Sumit Saurabh; Malabika Maulik; Shailesh N Khatri
Journal:  J Neurosci       Date:  2022-01-13       Impact factor: 6.709

3.  The Reversible Carnitine Palmitoyltransferase 1 Inhibitor (Teglicar) Ameliorates the Neurodegenerative Phenotype in a Drosophila Huntington's Disease Model by Acting on the Expression of Carnitine-Related Genes.

Authors:  Carla Bertapelle; Maria Rosaria Carillo; Nunzio Antonio Cacciola; Yulii V Shidlovskii; Gianfranco Peluso; Filomena Anna Digilio
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

4.  Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

Authors:  Miguel Moutinho; Juan F Codocedo; Shweta S Puntambekar; Gary E Landreth
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-12       Impact factor: 13.820

5.  Ketogenic diet improves behaviors in a maternal immune activation model of autism spectrum disorder.

Authors:  David N Ruskin; Michelle I Murphy; Sierra L Slade; Susan A Masino
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

Review 6.  Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases.

Authors:  Nicole Jacqueline Jensen; Helena Zander Wodschow; Malin Nilsson; Jørgen Rungby
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

Review 7.  Altered Cholesterol Homeostasis in Huntington's Disease.

Authors:  Radhia Kacher; Coline Mounier; Jocelyne Caboche; Sandrine Betuing
Journal:  Front Aging Neurosci       Date:  2022-04-19       Impact factor: 5.750

8.  Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases.

Authors:  Ziying Jiang; Xi Yin; Miao Wang; Tong Chen; Yuanyuan Wang; Zhongbao Gao; Zhenfu Wang
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

9.  HttQ111/+ Huntington's Disease Knock-in Mice Exhibit Brain Region-Specific Morphological Changes and Synaptic Dysfunction.

Authors:  Marina Kovalenko; Austen Milnerwood; James Giordano; Jason St Claire; Jolene R Guide; Mary Stromberg; Tammy Gillis; Ellen Sapp; Marian DiFiglia; Marcy E MacDonald; Jeffrey B Carroll; Jong-Min Lee; Susan Tappan; Lynn Raymond; Vanessa C Wheeler
Journal:  J Huntingtons Dis       Date:  2018

10.  Age-Dependent Degradation of Locomotion Encoding in Huntington's Disease R6/2 Model Mice.

Authors:  Hagar G Yamin; Noa Menkes-Caspi; Edward A Stern; Dana Cohen
Journal:  J Huntingtons Dis       Date:  2021
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.